page_title: Sibutramine
hierarchical_section_title: Sibutramine
caption_attribution_description: English: Ball-and-stick model of sibutramine — an oral anorexiant. Sibutramine is a racemic mixture, only (S)-(−)-enantiomer is portrayed. Created using Accelrys DS Visualizer 4.1 and Adobe Photoshop CC 2015. Colors used: &#160;&#160;Carbon,&#160;C:&#160;black &#160;&#160;Hydrogen,&#160;H:&#160;white &#160;&#160;Nitrogen,&#160;N:&#160;blue &#160;&#160;Chlorine,&#160;Cl:&#160;green This chemical image was created with Discovery Studio Visualizer.
context_page_description: Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with increased cardiovascular events and strokes and has been withdrawn from the market in several countries and regions including
  Australia, Canada, China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. However, the drug remains available in some countries.
  Sibutramine was originally developed in 1988 by Boots in Nottingham, U.K., and marketed by Knoll Pharmaceuticals after BASF/Knoll AG purchased the Boots Research Division in 1995, and was most recently manufactured and marketed by Abbott Laboratories before its withdrawal from most markets. It has been sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex. It is classified as a Schedule IV controlled substance in the United States.
context_section_description: Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with increased cardiovascular events and strokes and has been withdrawn from the market in several countries and regions including 
  Australia, Canada,China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. However, the drug remains available in some countries.
  Sibutramine was originally developed in 1988 by Boots in Nottingham, U.K., and marketed by Knoll Pharmaceuticals after BASF/Knoll AG purchased the Boots Research Division in 1995, and was most recently manufactured and marketed by Abbott Laboratories before its withdrawal from most markets. It has been sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex. It is classified as a Schedule IV controlled substance in the United States.
caption: Sibutramine (top),
  (S)-(−)-sibutramine (bottom)
exif: {}